Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October

Rhea-AI Summary

DURHAM, N.C., Sept. 28, 2020 – Precision BioSciences, a clinical stage biotechnology company listed on Nasdaq as DTIL, announced its participation in two upcoming virtual investor conferences. The events include the Chardan 4th Annual Genetic Medicines Conference on October 5, 2020, from 8:30 – 9:00 AM ET, and the Jefferies Cell Therapy Summit, also on the same day, from 5:30 – 6:00 PM ET. Webcasts of the presentations will be available on the company's website, with an archived replay accessible for about 30 days post-event.

News Market Reaction – DTIL

+5.71%

+5.71% Session move

In the trading session that priced this news, DTIL gained 5.71%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS^® genome editing platform, today announced its participation in the following upcoming virtual investor conferences:

• Chardan 4^th Annual Genetic Medicines Conference
  Date: Monday, October 5, 2020
  Time: 8:30 – 9:00 AM ET
  
  
• Jefferies Cell Therapy Summit
  Date: October 5, 2020
  Time: 5:30 – 6:00 PM ET

Live webcasts of each presentation will be accessible on the Company’s website www.precisionbiosciences.com, under the Investors & Media section. An archived replay of the webcasts will be available for approximately 30 days following the presentations.

About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS^® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

Investor and Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
maurissa.messier@precisionbiosciences.com

Josh Rappaport
Stern Investor Relations
josh.rappaport@sternir.com

 

FAQ

What is the date and time of Precision BioSciences' participation in the Chardan 4th Annual Genetic Medicines Conference?

Precision BioSciences will participate in the Chardan 4th Annual Genetic Medicines Conference on October 5, 2020, from 8:30 – 9:00 AM ET.

When is the Jefferies Cell Therapy Summit featuring Precision BioSciences?

The Jefferies Cell Therapy Summit featuring Precision BioSciences is scheduled for October 5, 2020, from 5:30 – 6:00 PM ET.

How can I access the webcasts of Precision BioSciences' conference presentations?

The webcasts of Precision BioSciences' conference presentations can be accessed on their website under the Investors & Media section.

Will there be a replay of the webcasts for Precision BioSciences' presentations?

Yes, an archived replay of the webcasts will be available for approximately 30 days following the presentations.

What is the focus of Precision BioSciences as a biotechnology company?

Precision BioSciences focuses on developing allogeneic CAR T therapies and in vivo gene correction therapies using its ARCUS genome editing platform.